Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells
- PMID: 12782597
Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells
Abstract
Both inactivation of p53 function and loss of sensitivity to Fas contribute to a malignant phenotype and frequently occur during tumor progression. Although in the majority of cases only one of the p53 alleles is mutated, some tumors acquire mutations in both alleles of the p53 gene. To determine the biological significance of this phenomenon, we analyzed p53 mutants, p53(223Leu) and p53(274Phe), from Fas-resistant prostate carcinoma cell line DU145. Both mutants differed from wild-type p53 in their conformation, transactivation ability, and effect on the growth of p53-deficient cells, with p53(223Leu) being more similar to wild-type p53 than was p53(274Phe). Interestingly, the biological effect of coexpression of the DU145-derived mutants was dramatically different from that of each mutant expressed alone. Whereas neither of the two mutants was found to be dominant-negative against wild-type p53, each neutralized the other's growth-suppressive effects and, in combination, were capable of down-regulating Fas expression and converting Fas-sensitive prostate carcinoma cells PC3 into Fas-resistant ones. These results indicate that two different p53 mutants that are separately rather weak can cooperate to generate p53 protein with anti-Fas function that is likely to provide additional selective advantages to the tumor.
Similar articles
-
p53 promotes selection for Fas-mediated apoptotic resistance.Cancer Res. 2000 Aug 15;60(16):4638-44. Cancer Res. 2000. PMID: 10969818
-
The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53.Prostate. 2006 Sep 15;66(13):1455-62. doi: 10.1002/pros.20462. Prostate. 2006. PMID: 16741917
-
Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.Cancer Res. 1991 Sep 1;51(17):4716-20. Cancer Res. 1991. PMID: 1873816
-
Gain-of-function mutations in the tumor suppressor gene p53.Clin Cancer Res. 2000 Jun;6(6):2138-45. Clin Cancer Res. 2000. PMID: 10873062 Review.
-
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.Cancer Res. 2000 Dec 15;60(24):6788-93. Cancer Res. 2000. PMID: 11156366 Review.
Cited by
-
Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):a026203. doi: 10.1101/cshperspect.a026203. Cold Spring Harb Perspect Med. 2016. PMID: 27235476 Free PMC article. Review.
-
Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness.Int J Mol Sci. 2016 Nov 26;17(12):1982. doi: 10.3390/ijms17121982. Int J Mol Sci. 2016. PMID: 27898034 Free PMC article. Review.
-
miR-449a enhances radiosensitivity through modulating pRb/E2F1 in prostate cancer cells.Tumour Biol. 2016 Apr;37(4):4831-40. doi: 10.1007/s13277-015-4336-8. Epub 2015 Oct 31. Tumour Biol. 2016. PMID: 26520443
-
Ceramide Synthase 6 Is a Novel Target of Methotrexate Mediating Its Antiproliferative Effect in a p53-Dependent Manner.PLoS One. 2016 Jan 19;11(1):e0146618. doi: 10.1371/journal.pone.0146618. eCollection 2016. PLoS One. 2016. PMID: 26783755 Free PMC article.
-
Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells.Oncogene. 2010 May 6;29(18):2628-37. doi: 10.1038/onc.2010.24. Epub 2010 Mar 1. Oncogene. 2010. PMID: 20190820 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous